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Summary Data from both rodents and humans show that testosterone reduces fear. This effect
is hypothesized to result from testosterone’s down regulating effects on the amygdala, a key
region in the detection of threat and instigator of fight-or-flight behavior. However, neuroimaging
studies employing testosterone administration in humans have consistently shown increased
amygdala responsivity. Yet, no study to date has investigated specifically how testosterone affects
the amygdala response to fearful emotional expressions. Such stimuli signal the presence of
environmental threat and elicit robust amygdala responses that have consistently been associated
with anxious traits. In the present study, we therefore used functional magnetic resonance
imaging combined with a single administration of 0.5 mg testosterone in 12 healthy women to
assess testosterone’s effects on amygdala responses to dynamic fearful (and happy control) faces.
Our results show that both stimuli activate the amygdala. Notably, testosterone increased the
amygdala response to both stimuli, and to an equal degree. Thus, testosterone appears not to
reduce fear by attenuating the amygdala response toward signals of threat. Data further show that
testosterone selectively increases activation of the superficial amygdala (SFA) and, to a lesser
extent, the basolateral amygdala (BLA). No effect was found in the central nucleus, which is
involved in the generation of autonomic fear responses. Both the SFA and BLA are considered input
regions, and enhanced activation by testosterone might reflect the role of this hormone in
adaptive responding to socially relevant stimuli. Furthermore, literature on the distinct roles of
the SFA and BLA in fear processing show that increased activation of these subregions of the
amygdala is consistent with a fear reducing effect of testosterone.
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Over the last decade, knowledge on the role of the steroid
hormone testosterone in human social and emotional beha-
vior has greatly increased. Working from models based on
effects of testosterone in mostly rodents, efforts have been
made to investigate the effects of testosterone in humans
(Eisenegger et al., 2011; Bos et al., 2012b). One of the results
of these efforts is the finding that testosterone, known to
reduce fear in rodents (Aikey et al., 2002), has comparable
effects in humans (van Honk et al., 2005; Hermans et al.,
2006, 2007). In these studies, a single administration of
testosterone resulted in reduced startle potentiation in
response to threat of mild electric shock (Hermans et al.,
2006), reduced sympathetic autonomic nervous system
responses to threatening pictures (Hermans et al., 2007),
and reduced automatic attention for fearful faces, which
signal environmental threat (Whalen et al., 2004; van Honk
et al., 2005). However, the neural mechanism by which
testosterone exerts these fear-reducing effects is currently
unknown.
A key structure implicated in anxiety and the detection of
salient environmental features including threat is the amyg-
dala (Davis and Whalen, 2001). Through its target regions
such as the hypothalamus and the periaqueductal gray (PAG),
the amygdala is tightly linked to networks involved in fear
responses and the initiation of fight-or-flight behavior (Price,
2003). Considering this role, it is not surprising this region is
very sensitive to emotional facial expressions (Phelps and
LeDoux, 2005). Dynamic facial expressions in particular have
been shown to elicit robust amygdala activation (Sato et al.,
2004; van der Gaag et al., 2007). Also, amygdala responses to
fearful faces presented outside of focal attention are
enhanced in highly anxious, but healthy, individuals (Bishop
et al., 2004), and especially in females (Dickie and Armony,
2008). Therefore, dysregulation of the amygdala has been
proposed to underlie the etiology of mood and anxiety dis-
orders. Indeed, patients suffering from mood and anxiety
disorders show exaggerated amygdala responses to emo-
tional faces compared to controls (Drevets, 2003; Monk,
2008), in particular toward fearful faces (Labuschagne
et al., 2010). Moreover, the amygdala is an important target
of testosterone, as it is rich in androgen receptors (Sarkey
et al., 2008), as well as in aromatase, which converts tes-
tosterone into estradiol (Biegon et al., 2010). Estradiol
receptors are also abundant in the human amygdala,
although they do not seem to be located in the central
nucleus of the amygdala (O¨sterlund et al., 2000). Finally,
males show faster attenuation of the amygdala in response to
fearful faces accompanied by lower autonomic stress
responses compared to females, who have lower baseline
testosterone levels (Williams et al., 2005). Based on these
findings, it can be hypothesized that testosterone exerts its
fear-reducing properties by reducing amygdala responses to
environmental threat cues.
However, studies investigating the effect of testosterone
on the amygdala performed so far show positive correlations
between endogenous testosterone levels and amygdala
responses to facial stimuli (Derntl et al., 2009; Stanton
et al., 2009; Manuck et al., 2010). Also, studies employing
a single administration of testosterone, which in contrast to
correlational methods can give causal insight, show increasedamygdala responses to faces after testosterone administra-
tion (Hermans et al., 2008; van Wingen et al., 2009). These
findings are not in favor of the hypothesis that testosterone
reduces fear by inhibiting the amygdala response. However,
such findings may also be explained by the fact that the
studies by Hermans et al. (2008) and van Wingen et al. (2009)
did not use fearful faces as stimuli to elicit amygdala activity.
For instance, Hermans et al. used angry and happy faces,
while van Wingen et al. presented fearful faces simulta-
neously with angry faces, making it impossible to distinguish
amygdala responses to these two expressions. Facial expres-
sions of fear are prototypical innate human danger cues that
are thought to evoke amygdala activity because they convey
the presence of threat without providing information about
its source, thus prompting sensory vigilance (Whalen, 1998;
Davis and Whalen, 2001). Indeed, fearful faces have been
shown to elicit stronger amygdala responses than angry faces
(Whalen et al., 2001), which are less ambiguous because they
directly represent the source of threat (Adams et al., 2003),
which is social in nature (van Honk et al., 2001; Hermans
et al., 2008). For these reasons, amygdala responses to the
expression of fear are thought to be more suitable to probe
neural processes underlying anxiety (Whalen et al., 2001;
Bishop et al., 2004; van Honk et al., 2005). The present study
therefore aimed to assess the effect of testosterone on the
amygdala response specifically to fearful faces.
In a counterbalanced placebo-controlled crossover
design, 12 healthy women were sublingually administered
0.5 mg of sublingual testosterone. Functional magnetic reso-
nance imaging (fMRI) was used to measure neural responses
to dynamic happy and fearful emotional faces, of which the
happy facial expressions served as a control condition (van
Marle et al., 2009). Happy and fearful faces were presented
in separate blocks to investigate the responses in our a priori
region of interest, the amygdala, to both emotional expres-
sions. This design allowed us to answer the question of
whether testosterone would reduce amygdala responses
toward signals of environmental threat, thereby potentially
decreasing fear.
Methods
Subjects
Twelve healthy, adult women with normal or corrected-to-
normal vision (age range 18—25; mean age 20.4) were tested
in a double-blind, placebo-controlled, fully counterbalanced
crossover design. Participants were mostly students
recruited from the university campus by advertisements.
Only women were included because the dosage and temporal
parameters of neurophysiological effects induced by a single
sublingual administration of testosterone are unknown in
men. Exclusion criteria were, for fMRI safety procedures:
history of closed-head injury, current pregnancy, and pre-
sence of metal objects in the body. To reduce interindividual
variability and avoid unwanted interactions with drug admin-
istration the following exclusion criteria were applied: his-
tory of endocrine or psychiatric disorders, irregular sleep
patterns, use of (recreational) psychotropic drugs within
2 weeks of testing, left hand dominance, and habitual smok-
ing. Nine women used standard monophasic estrogen/pro-
gestagen oral contraceptives. For the remaining three
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(first ten days after the first day of the menstruation) in order
to control for (minor) variations of androgen levels through-
out the menstrual cycle (see also Hermans et al., 2008).
Participants’ trait anxiety was assessed using the Spielberger
State-Trait Anxiety Inventory (STAI; Spielberger et al., 1983).
All scores were in the normal range (average 32.1; SD 8.2).
Written informed consent was obtained from all participants
and the study protocol was approved by the ethical review
board of the University Medical Center Utrecht in accordance
with the declaration of Helsinki. All participants received
financial compensation.
Testosterone administration
The testosterone sample consisted of 0.5 mg of testosterone,
5 mg of the carrier cyclodextrin, 5 mg of ethanol, and 0.5 ml of
water. The placebo sample was identical to the drug sample
only without containing testosterone. Both testosterone and
placebo were administered sublingually under supervision of
the experimenter. Extensive prior research established that
0.5 mg of testosterone in young women, without exception,
results in an approximate 10-fold increase in blood levels of
testosterone 15 min after administration, and a return to
baseline in 90 min (Tuiten et al., 2000). This 10-fold increase
mostly reflects testosterone that is bound to sex hormone
binding globulin (SHBG) and albumin, whereas the increase
of the free fraction, which passes the blood brain barrier and
exerts its effects in the brain, is increased more moderately. A
study into dose-dependent effects of sublingual testosterone
administration indeed shows that the increase of the free
fraction by testosterone depends on the SHBG level in women
(van Rooij et al., 2011). Behavioral and physiological effects of
the administration, as demonstrated by enhanced vaginal
pulse amplitude, peak 4 h after intake (Tuiten et al., 2000).
Numerous studies using various cognitive, emotional, and
neural measures have reported effects after this 4 h delay
(for a review, see Bos et al., 2012b). Therefore, the same 4 h
delay was used in the present study. For detailed description on
how the administration relates to the physiological testoster-
one levels in females and the generalizability of the data to
males, see Bos et al. (2010b).
Testosterone saliva measurements
Salivary sampling was based on Granger et al. (2004), which
has been successfully applied in several previous studies (e.g.
Bos et al., 2010b, 2012a). Testosterone in saliva was mea-
sured after diethylether extraction using a competitive
radio-immunoassay employing a polyclonal antitestoster-
one-antibody (Dr. Pratt AZG 3290). [1,2,6,7-3H]-Testosterone
(TRK402, Amersham Netherland B.V.) was used as a tracer
following chromatografic verification of its purity. The lower
limit of detection was 10 pmol/l and inter-assay variation
was 16.1, 11.5, and 5.1% at 21, 100, and 230 pmol/l respec-
tively (n = 4, 5, and 5).
Procedure
All participants were invited to the laboratory twice with an
interval of at least 1 week and procedures were identical onboth days. Appointments were scheduled 4 h before the scan
sessions. All participants were instructed not to eat within
1.5 h prior to the appointment and were allowed only to drink
water. After arrival, participants filled out the STAI-ques-
tionnaire and provided the saliva sample. After this, they
received the 0.5 ml drug sample (or placebo), and were
instructed to keep it under the tongue for a full minute. In
accordance with previous studies (Bos et al., 2012b), they
were allowed to swallow after this minute. They then
received instructions on the scanner procedure. After this,
participants were free to leave the laboratory and were
requested to return 3.5 h later. They were instructed to
avoid physically or psychologically straining activities within
this time. After verification of compliance and standard MRI
safety screening, participants were positioned in a supine
position on the scanner bed. Ear plugs were used to attenuate
scanner noise, and foam pads were placed inside the head
coil to restrict movement. Instructions and task images were
back-projected onto a translucent screen positioned near the
participants’ feet, which was visible through an angled mir-
ror mounted onto the head coil. The scanner room was dimly
lit throughout data acquisition. The participants first per-
formed the dynamic facial expression task (DFET), and after-
ward a monetary incentive delay task which is reported
elsewhere (Hermans et al., 2010).
Dynamic facial expression task (DFET)
The DFET consisted of blocks of facial stimuli which dynami-
cally and rapidly changed from neutral to full expressions.
There were eight blocks of happy expressions, eight blocks of
fearful expressions, and eight blocks of baseline fixation.
Each block lasted 26.7 s. Blocks were presented in a mirrored
design avoiding covariation of task regressors with linear
drift, in the following order: XFHXFHXFHXFHHFXHFXHFXHFX
(X = fixation; F = fearful; H = happy), with blocks of F and H
switched in a counterbalanced fashion across participants.
Participants were instructed to passively view the stimuli. To
control for attention, they were instructed to press a button
each time the fixation cross appeared. Stimuli were grayscale
ovals containing the faces from chin to forehead of 8 actors
taken from a standardized set of faces controlled for lumi-
nance and contrast (Ekman and Friesen, 1976). Morphing
sequences were computer generated animations consisting
of four frames (at 55%, 70%, 85%, and 100% of emotional
expression) with a total duration of 133 ms (created using
WinMorph 3.01). Animations of each actor were repeated
seven times within each block (i.e., 7  8 = 56 animations per
block, 476 ms SOA). Prior studies using dynamic emotional
faces have demonstrated robust amygdala activation (van
der Gaag et al., 2007; van Marle et al., 2009), also when
compared to static faces (Sato et al., 2004).
Scanning parameters
All scans were obtained using a 3 Tesla Philips Achieva MRI
scanner (Philips Medical Systems, Best, The Netherlands) with
a Quasar dual gradient set and an eight channel phased array
head coil. Whole brain T2* weighted 3D EPI images were
acquired with two-dimensional SENSitivity Encoding (SENSE;
see Pruessmann et al., 1999) acceleration. The following
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rior—posterior, inferior—superior, left—right): 224 mm
 256 mm  128 mm, voxel size: 4 mm isotropic, volume
acquisition time: 784 ms. Volumes were acquired in sagittal
orientation (coverage ear-to-ear), with frequency encoding in
the foot-head direction. SENSE was applied in anterior—pos-
terior and in left—right directions with acceleration factors
R = 2 and R = 1.8, respectively (see Neggers et al., 2008). This
fast and short TE sequence was designed specifically to mini-
mize signal dropout and image distortion due to magnetic field
inhomogeneity around air-tissue interfaces. 816 such images
were acquired for each session of the dynamic face task. For
each scan session, one additional (geometrically identical)
image was acquired with a larger flip angle (278), which yields
increased T1 weighting and hence higher gray—white matter
contrast. This image was used as an intermediate to improve
registration between functional and anatomical images. A T1-
weighted high resolution fast field echo structural scan was
obtained once for each participant using the following para-
meters: TE/TR: 2.3/25 ms, flip angle 308, FOV 256 mm
 150 mm  204 mm, voxel size: 1 mm isotropic, volume
acquisition time: 6 min 42 s.
fMRI data processing and analyses
MR scans were analyzed using SPM8 (www.fil.ion.ucl.ac.uk/
spm; Wellcome Department of Imaging Neuroscience, Lon-
don, UK). Motion correction was performed on all functional
scans using six parameter rigid body transformation and sum
of squared differences minimization. To facilitate registra-
tion of functional images with structural scans, we first
registered the functional scans to the 278 flip angle scan.
This scan was subsequently used to perform cross-modal
registration (six parameter rigid body transformation with
mutual information maximization) with the T1 weighted
structural image. Subsequently, all images were normalized
into standard (MNI152) space using affine transformations
and non-linear deformations, and resampled into 4 mm iso-
tropic voxels using fourth degree B-spline interpolation.
Finally, all images were smoothed using an 8 mm FWHM
Gaussian kernel to accommodate residual between subjects
variance in (functional) anatomy.
Statistical analysis of fMRI data was performed within the
general linear model framework using multi-session models
(testosterone and placebo) for each participant. Both face
conditions (happy vs. fearful faces) were modeled separately
as a box-car regressor for each session. These regressors
described the onset and duration of the blocks with morphing
faces, and were subsequently convolved with the canonical
hemodynamic response function included in SPM8. High pass
filter cut-off was set at 1/128 Hz. After estimating these
models, parameter estimate maps for both regressors of
interest (representing fearful and happy blocks) in the two
sessions (testosterone and placebo) were subjected to sec-
ond level random effects analyses using a factorial ANOVA
involving emotion (fear versus happy) and drug (testosterone
versus placebo) as within-subject factors. A covariate indi-
cating order of administration was included initially as a
between-subjects variable, but was removed from the model
because it did not explain additional variance. Alpha was set
at P < 0.05, corrected using random field theory based familywise error (FWE) corrections as implemented in SPM8. For our
main region of interest (amygdala), a small volume correc-
tion (SVC) was used that was based on an anatomical mask of
this region derived from the AAL template (Tzourio-Mazoyer
et al., 2002). Outside of this ROI, only statistical differences
exceeding a whole-brain FWE correction were considered
significant. Statistical parametric maps resulting from these
analyses were superimposed (using MRIcron: http://
www.sph.sc.edu/comd/rorden/mricron/) onto a high reso-
lution T1-weighted image of a single individual transformed
into MNI152 space. For visualization purposes, thresholds for
these images were set at P < 0.001, uncorrected. Inferential
statistics are listed in Table 1.
Finally, we performed a post hoc analysis to give insight
into the location of the testosterone-induced activation
within subregions of the amygdala. Based on cytoarchitec-
tonic probability maps, we made masks for the superficial
amygdala (SFA), the basolateral amygdala (BLA), and the
central-medial amygdala (CMA) (Amunts et al., 2005) by
applying a 0.5 probability threshold. To avoid blurring of
signal between these small subregions, we reran our first-
level model estimation on data to which no smoothing was
applied. We then extracted parameter estimates for each
emotion, drug, hemisphere, and amygdala subregion, and
averaged these values for each ROI. Resulting values were
entered into a 3  2  2  2 repeated measures ANOVA with
subregion (SFA, BLA, and CMA), hemisphere (left, right),
emotion (fear, happy), and drug (testosterone, placebo) as
within-subjects factors. A covariate indicating order of
administration was again omitted because it did not explain
additional variance. Additionally, post hoc repeated mea-
sures ANOVA’s with the same factors (hemisphere, emotion,
and drug) were performed in the three subregions separately
to further specify the effects.
Finally, to see whether baseline testosterone affected our
findings, testosterone values obtained from saliva (prior to
administration) were entered as a covariate. Extracted data
were analyzed using SPSS 20 with alpha set at 0.05.
Results
The contrast for the main effect of presentation of emotional
faces (happy and fearful faces combined versus rest) across
both sessions showed strong bilateral activation in a large
part of the occipital lobe extending into the inferior temporal
cortex, both involved in processing of visual information (see
Table 1 and Fig. 1 left panel). The same contrast yielded
bilateral activation in the amygdala, hippocampus, precen-
tral gyrus, temporal pole, parts of the frontal cortex, and the
triangular and orbital regions of the inferior frontal gyrus.
Although there was strong activation for the main contrast of
stimulus versus rest, no differential activation was found
when comparing the two stimulus types. When looking at
the effects of drug, a main effect of testosterone adminis-
tration was observed in the right amygdala (right panel),
which responded more strongly to the facial expressions after
testosterone compared to placebo (P < 0.05; SVC). No other
main effect or interaction of drug with stimulus type survived
the threshold of P < 0.05, whole brain FWE-corrected, or SVC
for the bilateral amygdala. Thus, no activation or deactiva-
tion was found other than reported above.
Table 1 Peak T values and corresponding MNI coordinates for significantly activated voxels.
Experimental effect Peak voxel location Peak T-values
Region x y z
Main effect: emotion > rest 41 71 7
Lingual gyrus R 19 95 5 18.09a
Middle occipital gyrus L 51 7 53 15.41a
Precentral gyrus L 53 3 49 7.56a
R 41 21 35 7.04a
Temporal pole R 39 21 35 6.90a
L 31 25 23 5.51a
IFG, orbital part L 37 37 15 6.17a
R 15 17 65 5.58a
Superior frontal gyrus L 45 17 25 6.14a
IFG, opercular part R 17 3 19 5.97a
Amygdala R 19 7 19 5.69a
L 7 65 29 5.55a
Medial superior frontal cortex L 39 5 61 5.48a
Middle frontal cortex L 15 61 33 5.31a
Superior frontal cortex L 15 53 11 5.29a
Superior orbitofrontal cortex L 61 5 19 5.29a
Middle temporal pole R 63 11 33 5.27a
Postcentral gyrus L 55 25 9 5.23a
IFG, triangular part L 5.17a
Main effect: testosterone > placebo 25 7 15
Amygdala R 4.16b
R, right; L, left; IFG, inferior frontal gyrus.
a Whole brain FWE corrected at P < 0.05.
b Small volume corrected at P < 0.05.
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tigate which subregions within the amygdala are most
strongly affected by testosterone administration (see
Fig. 2). Averaged parameter estimates extracted from
unsmoothed data within each of the three anatomically
defined subregions were entered into a repeated measures
ANOVA. In agreement with statistical parametric mapping
analyses reported above, this ANOVA yielded a main effect of
drug (F(2,10) = 4.55, P = 0.039; h2 = 0.48) and did not reveal
any main effect or interaction involving the factor emotion.
However, the main effect of drug was qualified by a drug by
subregion interaction (F(4,8) = 4.10, P = 0.043; h2 = 0.67),
indicating that the effect of testosterone differed between
subregions. Further post hoc testing within the subregions
(see Fig. 2) revealed that the testosterone effect was most
prominent in the SFA (F(2,10) = 8.57, P = 0.007; h2 = 0.63). In
the BLA there was no significant effect of drug, although
there was a trend toward stronger responses after testoster-
one (F(2,10) = 2.95, P = 0.098; h2 = 0.37). In the CMA, no
effect of drug was found (F(2,10) = 0.31, P = 0.74;
h2 = 0.06). A significant main effect or interaction involving
hemisphere was found in neither of the three subregions,
indicating that the effect of testosterone was not lateralized.
Notably, BOLD responses to presentation of faces across
drug conditions also varied between subregions (main effect
of subregion: F(4,8) = 17.42, P = 0.001; h2 = 0.90), with sig-
nificant responses only in the SFA (F(2,10) = 15.2, P = 0.001;
h2 = 0.75) and BLA (F(2,10) = 25.47, P < 0.001; h2 = 0.84),
but not in the CMA (F < 1, n.s.). Finally, we tested whether
testosterone baselines correlated with amygdala activation,or with the effect of testosterone, but testosterone baseline
did not explain any variance in the data (all P-values > 0.05).
Discussion
In this study we attempted to investigate the mechanism
whereby testosterone reduces fear in humans, and tested the
specific hypothesis that testosterone would reduce amygdala
activation in response to a prototypical innate human danger
cue: the fearful face. Contrary to the hypothesis, testoster-
one administration increased the amygdala response to both
fearful and happy faces, of which the happy faces served as a
control condition. Additional analyses showed that this effect
of testosterone was most pronounced in the superficial
amygdala (SFA), extended marginally into the basolateral
amygdala (BLA), but did not encompass the central-medial
amygdala (CMA). Although these findings do not support our
hypothesis, they are consistent with an earlier study that
showed a positive correlation between endogenous testos-
terone levels and amygdala activation in response to (static)
fearful faces (Derntl et al., 2009). Moreover, they correspond
with previous testosterone administration studies that have
shown increased amygdala responses to emotional faces
(Hermans et al., 2008; van Wingen et al., 2009).
In the current study, we could not replicate previous
findings of a stronger amygdala response to fearful than to
happy facial expressions (e.g. Whalen et al., 2001). Our
finding of comparably strong amygdala activation to fearful
and happy faces is in line with recent literature showing
Figure 1 Coronal, sagittal, and axial slices with accompanying MNI coordinates of the Y-, X-, and Z-axis of the t-maps for the main
effects of faces vs. rest and testosterone vs. placebo. The t-maps are thresholded at P < 0.001 uncorrected for illustration purposes
and overlaid onto a T1-weighted canonical image.
Testosterone increases amygdala responses to fearful and happy faces 813non-specific amygdala responses to emotional faces (e.g.
Sato et al., 2004; van der Gaag et al., 2007; Goossens
et al., 2009). Such findings, together with those obtained
in the present study, do not concur with the notion that the
amygdala is a region that is specifically involved in fear
processing. Instead, the emerging view is that the amygdala
plays a more general role in detection and processing of
salient information including facial expressions (Whalen,
1998; Davis and Whalen, 2001; Sander et al., 2003; Goossens
et al., 2009).
Notably, our data also show that the amygdala response to
facial expressions is mostly carried by the SFA and the BLA,
but not the CMA. This finding corresponds with a number of
previous studies showing that the SFA and BLA are especially
sensitive to facial stimuli (Hoffman et al., 2007; Ball et al.,2009; Goossens et al., 2009). Moreover, effects of testoster-
one administration were also confined to these two subre-
gions, although the potentiation of the BLA response was only
significant at trend-level. Since the SFA and BLA are consid-
ered mostly as input regions, the increased activation of
these subregions might reflect increased processing of
socially relevant stimuli by testosterone. Studies in rats
further show that the medial nucleus, which is adjacent to
the SFA, is highly sensitive to androgens, and testosterone
can structurally and functionally influence the medial
nucleus (Cooke et al., 1999; Pitka¨nen et al., 2000; Johnson
et al., 2012). In agreement, the human SFA is selectively
enlarged in males, which might indicate sensitivity of this
region to testosterone in humans as well (Kim et al., 2012).
Furthermore, a functional neuroimaging study which inves-
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Figure 2 Parameter estimates extracted from the anatomically defined subregions of the bilateral amygdalae in the placebo and
testosterone condition, for happy and fearful faces (L = left; R = right; CMA = central-medial amygdala; BLA = basolateral amygdala;
SFA = superficial amygdala).
814 P.A. Bos et al.tigated the relation between testosterone levels and amyg-
dala activation showed a positive correlation of testosterone
baseline specifically with the dorsal part of the amygdala
(Manuck et al., 2010). In this ventral/dorsal distinction of the
amygdala, the dorsal part encompasses the CMA, the region
where we did not find an effect of testosterone, but also parts
of the SFA. In fact, the peak location for activation in the
dorsal amygdala reported by Manuck et al. corresponds most
strongly to the SFA in the cytoarchitectonic probability maps
used in the present study (Amunts et al., 2005). It is therefore
well possible that the effect reported by Manuck et al. is
caused by testosterone acting on the SFA, which would
correspond to our findings. Finally, also an indirect effect
of estradiol, converted from testosterone, could be pro-
posed, as these receptors in humans have been shown to
be abundant in the amygdala, but not in the central nucleus
(O¨sterlund et al., 2000).
Overall, heightened sensitivity for socially relevant sti-
muli concurs with the challenge hypothesis, a framework
which states that the function of testosterone is to deal with
environmental challenges (Wingfield et al., 1990; Archer,
2006; Bos et al., 2012b). In such a challenge framework,
testosterone facilitates any form of adaptive goal-directed
behavior, such as increased sensitivity to socially relevant
signals, more aggression in situations of conflict, and also a
reduction of fear to immediate threat. Thus, activation of
the SFA and BLA by testosterone may indicate more elaborate
processing of social signals in the absence of a fear response.
The present data raise the question how testosterone, if
not by reducing activation of the amygdala, reduces fear. One
relevant aspect of testosterone with regard to this question
was brought to light by the studies investigating the fear
reducing effect of testosterone in humans. These studies
showed that this hormone reduces phasic ‘‘fear’’ responses
rather than tonic background ‘‘anxiety’’ (van Honk et al.,
2005; Hermans et al., 2006). For instance, Hermans et al.
(2006, 2007) showed that testosterone specifically reduces
the cue-specific fear potentiation of the startle reflex, but
does not affect baseline startle responses. This effect of
testosterone is unlike that of anxiolytics such as benzodia-
zepines, which reduce baseline startle rather than fearpotentiated startle (Baas et al., 2002; Grillon, 2002). Base-
line startle is a measure that is proposed to relate to con-
sciously experienced anxiety, which concurs with the
common use of benzodiazepines in patients suffering from
anxiety disorders. In contrast, fear potentiation of the startle
reflex, which is targeted by testosterone, is a response that is
triggered by a discrete threat cue. Moreover, in the study by
van Honk et al. (2005) testosterone only reduced fear
responses to fearful facial expressions presented below the
threshold of conscious perception, while it did not affect
conscious measures of anxiety. Together, these studies
demonstrate that testosterone may reduce fear rather than
anxiety, a distinction that might aid the interpretation of our
current data.
A distinction between fear-related processes can also be
found in the different subregions of the amygdala. As men-
tioned above, the SFA and BLA are mostly input regions for
sensory information, while the CMA is an output region,
projecting downstream to brainstem regions such as the
PAG and hypothalamus (Pitka¨nen et al., 2000; Price, 2003).
Thus, the CMA is most strongly involved in the generation of
autonomic fear responses, while BLA responses are more
related to fear learning (Davis and Whalen, 2001; Phelps
and LeDoux, 2005). Also, the medial nucleus, which as
described above is adjacent to the SFA and is sensitive to
androgens, has in rodents been implicated in emotional stress
responses, but not physical stress responses, while the CMA
shows an opposite pattern (Ebner et al., 2004). Recent rodent
data moreover show that the functions of the amygdala
subregions are not only dissociated, but that the BLA is even
capable of reducing CMA output (Macedo et al., 2007; Tye
et al., 2011). Together, a selective effect of testosterone on
the fear response and the distinct roles of amygdala sub-
regions in fear processing imply that fear reduction induced
by testosterone is consistent with increased activation of the
SFA or BLA.
A limitation of the current study is that the paradigm used
was specifically designed with dynamic emotional expres-
sions to elicit robust amygdala activation. It is well possible
that the strong amygdala activation obscured subtle differ-
ences between emotional expressions induced by testoster-
Testosterone increases amygdala responses to fearful and happy faces 815one administration that have been found with static faces in
previous studies (Hermans et al., 2008). Also, the use of
consciously perceived stimuli may have affected our data.
Previous studies have often used stimuli presented outside of
conscious awareness or focal attention to study neural
responses related to fear and anxiety (Bishop et al., 2004;
Whalen et al., 2004; Dickie and Armony, 2008). Since the
testosterone-induced reduction of attention for fearful faces
reported by van Honk et al. (2005) was specific to uncon-
sciously presented faces, and since modulation of awareness
can affect subregions of the amygdala differently (Lerner
et al., 2012), a future study should combine testosterone
administration with unconsciously presented faces to address
this issue. Further suggestions would be to include a neutral
condition, which is not feasible using dynamic facial stimuli,
and a non-face condition to control for specificity to facial
stimuli. Moreover, future research should assess autonomic
nervous system measures of fear simultaneously with neural
activation, for instance using threat of shock procedures
(Hermans et al., 2006). Such a setup may give more direct
insight into the question how increased responses in the SFA
and perhaps BLA may relate to reductions in fear responses.
A final point of consideration is that this study was per-
formed only in women, which raises the question whether
these findings also apply to the other sex. Indeed, gender
differences have been reported in mood disorders, with
females being more prone to anxiety disorders (Piccinelli
and Wilkinson, 2000). In agreement, numerous neuroimaging
studies have reported sexually dimorphic responses during
emotion processing (Cahill, 2006; Derntl et al., 2010).
Females tend to have stronger amygdala responses that
are more lateralized to the left hemisphere while males
show the opposite pattern (Williams et al., 2005; Cahill,
2006; Schneider et al., 2011); but see Dickie and Armony
(2008), and Etkin et al. (2004), for conflicting findings.
Although in the current study there was no statistically
significant difference between the testosterone effect in
the subregions of the left and right amygdala, it appeared
more pronounced on the right side of the brain, which is in
line with previous testosterone administration studies (Bos
et al., 2010a, 2012a; Hermans et al., 2010). Whether these
findings relate to the reported sex differences remains a
topic for further investigation, but based on correlational
data in women we expect the effects of testosterone admin-
istration to be similar for males and females (van Honk et al.,
1999, 2001). A more detailed discussion on generalizability,
and the administration procedures in women can be found in
Bos et al. (2010b, 2012b).
In this study, we tested the hypothesis that testosterone
would decrease amygdala activation in response to fearful
faces. In contradiction to this hypothesis, testosterone
increased the amygdala response to both fearful and happy
faces, suggesting that testosterone does not reduce fear by
down regulating the amygdala response. Our finding that
testosterone acted most prominently on input regions of
the amygdala (i.e., SFA and to a lesser extent BLA) suggests
that testosterone may promote preferential processing of
salient stimuli in the context of social challenges. Finally, the
literature on distinct roles of amygdala subregions in
fear-related processes indicates that increased responses
in SFA and BLA concur with fear-reducing properties of
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